HALO vs ACAD Stock Comparison: AI Score, Valuation, Performance and Upside
HALO operates a capital-light drug delivery technology licensing business with growing, high-margin royalty streams from partner drugs, while ACAD is a direct drug developer with two approved CNS drugs facing commercial challenges and ongoing pipeline investment. Both are mid-cap biotechs but with fundamentally different business models and risk profiles.
HALO vs ACAD compares a capital-light drug delivery technology licensor with growing royalty streams against a direct CNS drug developer with approved products navigating commercial execution challenges.
HALO holds the edge across 4 of 5 key metrics in this comparison. HALO leads on both 1-year return (+97.81%) and forward P/E quality (10.48x vs 21.43x for ACAD), a relatively favorable combination of momentum and valuation. HALO leads on both revenue growth (47.70%) and operating margin (59.80%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for ACAD (+54.72%) than for HALO (-8.62%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want exposure to a capital-light, high-margin drug delivery technology royalty business
- Value the diversification from multiple approved partner drugs generating Halozyme royalties
- Appreciate the lower clinical risk profile versus direct drug development
- Want exposure to a CNS drug developer with two approved commercial products
- Believe Daybue adoption in Rett syndrome will improve as physician and patient experience grows
- See value in Acadia's pipeline potential beyond its current approved drugs
| Metric | HALO | ACAD |
|---|---|---|
| AI scorei | 67.2 | 25.7 |
| AI ranki | #121 | #2663 |
| Latest closei | $128.95 | $20.47 |
| 1M returni | +17.38% | +2.61% |
| 3M returni | +56.74% | -20.07% |
| 6M returni | +99.71% | -7.75% |
| 1Y returni | +97.81% | -9.82% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | HALO | ACAD |
|---|---|---|
| 1Y ago | $19.48K (+94.8%) started 2025-11-03 | $9.15K (-8.5%) started 2025-11-03 |
| 5Y ago | $32.2K (+222.0%) started 2021-11-03 | $10.05K (+0.5%) started 2021-11-03 |
| 10Y ago | $152.42K (+1424.2%) started 2016-11-03 | $9.81K (-1.9%) started 2016-11-03 |
Hypothetical — past performance does not guarantee future results.
| Metric | HALO | ACAD |
|---|---|---|
| Market capi | $12.37B | $3.4B |
| Trailing P/Ei | 31.95 | 8.85 |
| Forward P/Ei | 10.48 | 21.43 |
| Price/Salesi | N/A | N/A |
| EV/Revenuei | 8.52 | 2.21 |
| Analyst targeti | $99.56 | $30.53 |
| Target upsidei | -8.62% | +54.72% |
| Metric | HALO | ACAD |
|---|---|---|
| Revenue growthi | 47.70% | 16.40% |
| Earnings growthi | 42.90% | 13.30% |
| EPS growthi | +42.90% | +13.30% |
| FCF margini | +20.27% | +6.03% |
| Operating margini | 59.80% | 12.29% |
| Profit margini | 24.86% | 33.42% |
| ROIC proxyi | 173.67% | 35.74% |
| Return on equityi | 173.67% | 35.74% |
| Dividend yieldi | N/A | 0.00% |
| Payout ratioi | 0.00% | 0.00% |
| Dividend growth streaki | N/A | N/A |
| Betai | 0.85 | 0.89 |
| Debt/equityi | 1517.69 | 5.65 |
| Current ratioi | 2.71 | 3.39 |
| Quick ratioi | 1.99 | 3.11 |
Over the past year, HALO and ACAD have moved weakly in the same direction (correlation of 0.27), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | HALO | ACAD |
|---|---|---|---|
| 1Y | Growthi | +94.79% | -8.49% |
| CAGRi | +95.19% | -8.52% | |
| Volatilityi | 37.53% | 38.73% | |
| Sharpe ratioi | 1.86 | -0.15 | |
| Sortino ratioi | 3.44 | -0.21 | |
| Max drawdowni | 24.13% | 39.09% | |
| Current drawdowni | 1.70% | 33.04% | |
| Avg drawdowni | 8.30% | 14.60% | |
| Ulcer Indexi | 11.22% | 18.29% | |
| Max daily dropi | 9.01% | 12.78% | |
| Max wkly dropi | 13.36% | 24.22% | |
| 5Y | Growthi | +221.97% | +0.49% |
| CAGRi | +26.36% | +0.10% | |
| Volatilityi | 40.40% | 54.91% | |
| Sharpe ratioi | 0.67 | 0.20 | |
| Sortino ratioi | 1.00 | 0.29 | |
| Max drawdowni | 49.06% | 57.87% | |
| Current drawdowni | 1.70% | 38.84% | |
| Avg drawdowni | 17.33% | 32.64% | |
| Ulcer Indexi | 21.65% | 35.64% | |
| Max daily dropi | 24.56% | 33.32% | |
| Max wkly dropi | 31.69% | 24.96% | |
| 10Y | Growthi | +1424.23% | -1.92% |
| CAGRi | +31.32% | -0.19% | |
| Volatilityi | 42.40% | 61.70% | |
| Sharpe ratioi | 0.75 | 0.23 | |
| Sortino ratioi | 1.14 | 0.35 | |
| Max drawdowni | 49.06% | 77.18% | |
| Current drawdowni | 1.70% | 64.09% | |
| Avg drawdowni | 16.40% | 47.10% | |
| Ulcer Indexi | 19.99% | 52.30% | |
| Max daily dropi | 24.56% | 45.35% | |
| Max wkly dropi | 31.69% | 46.70% |
| Category | HALO | ACAD |
|---|---|---|
| Company | Halozyme Therapeutics, Inc. | Acadia Pharmaceuticals Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Core business | Halozyme develops and licenses its ENHANZE drug delivery technology — using recombinant human hyaluronidase (rHuPH20) — enabling large-molecule drugs to be delivered subcutaneously (under the skin) instead of intravenously, offering convenience benefits for patients with existing biologics. | Acadia Pharmaceuticals develops drugs for central nervous system (CNS) conditions, with approved products including Nuplazid (pimavanserin) for Parkinson's disease psychosis and Daybue (trofinetide) for Rett syndrome, a rare pediatric neurological disorder. |
| Investor focus | Investors track Halozyme's ENHANZE royalty revenue growth as partner drugs launch subcutaneous formulations, the number of approved and pipeline ENHANZE-partnered drugs, and Halozyme's capital return program. | Investors track Daybue's Rett syndrome patient uptake and revenue growth, Nuplazid's commercial trajectory, and Acadia's pipeline including additional CNS indications. |
- Capital-light royalty business model generates high-margin, recurring revenue from partner drug sales without Halozyme needing to own or market drugs directly
- ENHANZE has been adopted by major pharma companies including Roche, Johnson & Johnson, AstraZeneca, and others
- Growing royalty streams from multiple approved partner drugs provide revenue diversification
- Nuplazid is the only FDA-approved drug specifically for Parkinson's disease psychosis, providing a defined and durable niche
- Daybue is the first-ever approved treatment for Rett syndrome, establishing Acadia in the rare neurological disease space
- CNS disease focus provides potential for additional orphan designations and pipeline leverage
- Royalty revenue is dependent on partner drug commercial success — if a partnered drug fails or underperforms, royalty streams disappoint
- Technology licensing model provides less upside than owning drug franchises directly
- Competition from other subcutaneous delivery technologies could reduce future partner uptake
- Daybue tolerability concerns (particularly gastrointestinal side effects) have limited patient uptake versus initial expectations
- Nuplazid has faced persistent safety scrutiny and limited prescription growth due to the challenging Parkinson's disease patient management context
- High operating expenses relative to revenue keep Acadia loss-making
Compare more than two at a time
This page is a fixed writeup on HALO and ACAD. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside HALO and ACAD, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.